drugset / Trial / NCT05893381
Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST)
Phase 2
Recruiting
70 enrolled
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
RandomizedParallel-groupOpen-labelTreatment
Summary
Multicenter, open-label, parallel-group, phase II randomized study in patients with oligometastatic prostate cancer with 1-3 asymptomatic metastases of the soft tissue or bone. Eligible patients will be randomized at 1:1 ratio to Stereotactic Radiotherapy followed by Lu-PSMA (arm A) or Stereotactic Radiotherapy (arm B)
Timeline
- Start
- 2023-06-27
- Primary completion
- 2027-09
- Completion
- 2032-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LUTETIUM LU 177 ZADAVOTIDE GURAXETAN | Other / unclassified | 7400 mbq | Intravenous |